NASDAQ:SRRK - Scholar Rock Stock Price, Forecast & News

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Scholar Rock Holding Corp (NASDAQ:SRRK) released its earnings results on Tuesday, November, 12th. The company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.22. The firm earned $4.77 million during the quarter, compared to analysts' expectations of $12.73 million. View Scholar Rock's Earnings History.

Scholar Rock is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Scholar Rock.

2 analysts have issued 12-month target prices for Scholar Rock's stock. Their forecasts range from $27.00 to $27.00. On average, they expect Scholar Rock's stock price to reach $27.00 in the next year. This suggests a possible upside of 57.5% from the stock's current price. View Analyst Price Targets for Scholar Rock.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scholar Rock.

Media headlines about SRRK stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Scholar Rock earned a news impact score of 4.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Scholar Rock.

Some companies that are related to Scholar Rock include Alector (ALEC), Regenxbio (RGNX), Bill.com (RVMD), Coherus Biosciences (CHRS), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Beam Therapeutics (BEAM), Editas Medicine (EDIT), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX), Twist Bioscience (TWST), I-Mab (BDTX), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS) and Aerie Pharmaceuticals (AERI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Global Blood Therapeutics (GBT), Coherus Biosciences (CHRS), Exelixis (EXEL), Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), Thermo Fisher Scientific (TMO), ACADIA Pharmaceuticals (ACAD) and Atara Biotherapeutics (ATRA).

(SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Scholar Rock's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (1.19%), Victory Capital Management Inc. (0.84%), Victory Capital Management Inc. (0.83%), Geode Capital Management LLC (0.80%), Jefferies Group LLC (0.42%) and Point72 Asset Management L.P. (0.26%). Company insiders that own Scholar Rock stock include Amir Nashat and International SCA Artal. View Institutional Ownership Trends for Scholar Rock.

SRRK stock was sold by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Marshall Wace LLP, Alberta Investment Management Corp, Panagora Asset Management Inc. and Credit Suisse AG. View Insider Buying and Selling for Scholar Rock.

SRRK stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Victory Capital Management Inc., Victory Capital Management Inc., State Street Corp, Goldman Sachs Group Inc., California Public Employees Retirement System, Barclays PLC and Citigroup Inc.. Company insiders that have bought Scholar Rock stock in the last two years include Amir Nashat and International SCA Artal. View Insider Buying and Selling for Scholar Rock.

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SRRK stock can currently be purchased for approximately $17.14.

Scholar Rock has a market capitalization of $508.68 million. The company earns $-49,330,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Scholar Rock employs 65 workers across the globe.View Additional Information About Scholar Rock.

The official website for Scholar Rock is http://www.scholarrock.com/.

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]